Acurx Pharmaceuticals, Inc.
NASDAQ:ACXP
0.7 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Acurx Pharmaceuticals, Inc. |
Symbool | ACXP |
Munteenheid | USD |
Prijs | 0.699 |
Beurswaarde | 13,626,096 |
Dividendpercentage | 0% |
52-weken bereik | 0.68 - 5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. David P. Luci CPA, CPA, Esq., J.D. |
Website | https://www.acurxpharma.com |
An error occurred while fetching data.
Over Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)